COVID-19 / Coronavirus

Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success

2024-04-19 21:00 1053

* To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank * Planning to initiate global multinational clinical projects in digital therapeutics * Establishing a future medical system centered aroun...

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

2024-04-19 13:17 853

SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue vi...

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

2024-04-19 10:54 967

SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue...

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

2024-04-18 20:00 859

GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

TaiGen Successfully Completes TG-1000 Phase III Study

2024-04-18 11:03 959

TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of al...

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA

2024-04-17 14:03 1279

— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Vietnamese Organizations Institute of Gastroenterology and Hepatology and ...

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA

2024-04-17 11:22 1326

— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Indian Organizations Chennai Liver Foundation and FIND Receive the Grant t...

Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

2024-04-16 22:00 1194

SHANGHAI, April 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) An...

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

2024-04-16 20:00 1541

GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

Exploring Pioneering Programs in Medical Integration in the Greater Bay Area: Actively Applying Digital Identity and Global Legal Entity Identifier (LEI)

2024-04-16 19:05 1127

HONG KONG, April 16, 2024 /PRNewswire/ -- With the rapid development in information technology, digital transformation has become a core driver in promoting the integration of various sectors in the Greater Bay Area (GBA). In the GBA, a pioneering program has been carried out to explore the poten...

Asian Plastics & Rubber Industry Online Exhibition 2024 Grand Opening

2024-04-16 14:59 1230

TAIPEI, April 16, 2024 /PRNewswire/ -- Asian Plastics & Rubber Industry Online Exhibition (AsianPLAS 2024) is a virtual and physical integration targeting Asian suppliers, importers, and exporters. It will be exhibited fromApril 23, 2024, to October 31, 2024, and will be an excellent opportunity ...

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

2024-04-15 13:06 1087

– Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant – – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – – South Korea's Association of Liver Patients and Survivors and the Taiwan re...

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG

2024-04-15 12:22 1063

-- Gilead Awards US$4 Million Globally (Excluding the United States) Through The Gilead ALL4LIVER Grant -- -- World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee -- -- Hong Kong Liver Foundation and Hong Kong Liver Transplant Patients' ...

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

2024-04-09 20:00 1160

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

2024-04-08 22:00 1006

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...

Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"

2024-04-08 20:00 1551

* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...

Datasea Enters into a Sales Agreement for its Acoustic Products Bringing its Evolutionary Technology to Market in a Strategic Milestone to Develop Rapid Online Sales

2024-04-04 22:00 1527

BEIJING, April 4, 2024  /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and C...

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

2024-04-03 20:00 1556

GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

WuXi Biologics Reports Solid 2023 Annual Results

2024-03-26 21:53 1115

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...

12345 ... 225